JP2023542124A - 多発性骨髄腫を治療するための方法 - Google Patents

多発性骨髄腫を治療するための方法 Download PDF

Info

Publication number
JP2023542124A
JP2023542124A JP2023517243A JP2023517243A JP2023542124A JP 2023542124 A JP2023542124 A JP 2023542124A JP 2023517243 A JP2023517243 A JP 2023517243A JP 2023517243 A JP2023517243 A JP 2023517243A JP 2023542124 A JP2023542124 A JP 2023542124A
Authority
JP
Japan
Prior art keywords
dose
subject
bispecific antibody
gprc5d
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542124A5 (cg-RX-API-DMAC7.html
Inventor
ガーギス,スゼット
ゴールドバーグ,ジェナ
ヒルダー,ブランディ
マ,スーウェン
ラッセル,ジェフリー
ヴェロナ,ラルカ
ヤング,シイ
ピラリゼッティ,コダンダラム
Original Assignee
ヤンセン バイオテツク,インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク,インコーポレーテツド filed Critical ヤンセン バイオテツク,インコーポレーテツド
Publication of JP2023542124A publication Critical patent/JP2023542124A/ja
Publication of JP2023542124A5 publication Critical patent/JP2023542124A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Luminescent Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023517243A 2020-09-16 2021-09-16 多発性骨髄腫を治療するための方法 Pending JP2023542124A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063079294P 2020-09-16 2020-09-16
US63/079,294 2020-09-16
US202063116549P 2020-11-20 2020-11-20
US63/116,549 2020-11-20
US202163187888P 2021-05-12 2021-05-12
US63/187,888 2021-05-12
PCT/EP2021/075523 WO2022058445A1 (en) 2020-09-16 2021-09-16 Methods for treating multiple myeloma

Publications (2)

Publication Number Publication Date
JP2023542124A true JP2023542124A (ja) 2023-10-05
JP2023542124A5 JP2023542124A5 (cg-RX-API-DMAC7.html) 2024-09-25

Family

ID=77924410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517243A Pending JP2023542124A (ja) 2020-09-16 2021-09-16 多発性骨髄腫を治療するための方法

Country Status (11)

Country Link
US (1) US20220177584A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213945A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542124A (cg-RX-API-DMAC7.html)
KR (1) KR20230069959A (cg-RX-API-DMAC7.html)
CN (1) CN116322769A (cg-RX-API-DMAC7.html)
AU (1) AU2021346129A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3194796A1 (cg-RX-API-DMAC7.html)
IL (1) IL301361A (cg-RX-API-DMAC7.html)
MX (1) MX2023003086A (cg-RX-API-DMAC7.html)
WO (1) WO2022058445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP4585615A4 (en) 2022-09-09 2026-07-08 Beijing Mabworks Biotech Co Ltd Multispecific antibody binding to BCMA, GPRC5D and CD3 and its use
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
TW202448927A (zh) * 2023-02-28 2024-12-16 美商健生生物科技公司 包含雙特異性gprc5d/cd3抗體之組成物
EP4698217A1 (en) * 2023-04-19 2026-02-25 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
AU2024370419A1 (en) 2023-10-31 2026-06-11 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. VOLUME 135, NUMBER 15, JPN6025040583, 9 April 2020 (2020-04-09), pages 1232 - 1243, ISSN: 0005912656 *
CLINICALTRIALS.GOV ,NCT03399799 [ONLINE](RETRIEVED ON 2025 SEP 25), VER.20:2020-9-10UPLOADED,RETRI, JPN6025040582, 10 September 2020 (2020-09-10), ISSN: 0005912657 *

Also Published As

Publication number Publication date
BR112023004830A2 (pt) 2023-04-18
KR20230069959A (ko) 2023-05-19
IL301361A (en) 2023-05-01
EP4213945A1 (en) 2023-07-26
CA3194796A1 (en) 2022-03-24
US20220177584A1 (en) 2022-06-09
MX2023003086A (es) 2023-06-16
CN116322769A (zh) 2023-06-23
WO2022058445A1 (en) 2022-03-24
AU2021346129A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US11952426B2 (en) Methods for treating multiple myeloma
US12098210B2 (en) Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies
US20220177584A1 (en) Methods for treating multiple myeloma
KR20250097946A (ko) 암을 치료하는 방법
US20250064928A1 (en) Methods for treating multiple myeloma
US20240415960A1 (en) Methods for treating multiple myeloma
US20230295292A1 (en) Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies
EA050839B1 (ru) Способы лечения множественной миеломы
WO2025094085A1 (en) Combination regimens for treating multiple myeloma
KR20260020402A (ko) 다발성 골수종의 치료 방법
CN118414165A (zh) 治疗癌症并增强BCMAxCD3双特异性抗体的功效的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721